Focus: Athena Bioscience is a specialty pharmaceutical company headquartered in Watkinsville, GA, focused on neurology and related therapeutic areas with an established portfolio of marketed drugs.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Athena Bioscience offers specialty pharma stability through established products but faces immediate headwinds from recent layoffs and an apparent pipeline vacuum—suitable only for candidates prioritizing near-term income over long-term growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Extended-release alpha-2 agonist in peak commercial phase with patent protection through 2031, providing mid-term revenue certainty.
Help build intelligence for Athena Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Athena Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lipid-modifying delayed-release capsule facing loss of exclusivity in 2027; revenue erosion likely within 3–4 years unless repositioned or reformulated.
2 discontinued, 0 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
The March 2025 layoff is a material red flag; combined with minimal hiring, it suggests the company is in contraction mode and at elevated risk for further workforce reductions.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo